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Pulmonology Oncology, University Hospital Groningen (UMCG), Groningen, NETHERLANDS 2 Medical Oncology, University Hospital Groningen (UMCG), Groningen, NETHERLANDS 3 Pathology, University Hospital Groningen (UMCG), Groningen, NETHERLANDS 4 Epidemiology, University Hospital Groningen (UMCG), Groningen, NETHERLANDS Aim: Markers of epithelial to mesenchymal transition (EMT) and markers associated with cancer stem cells (CSC) have been associated with increased chemoresistance in small cell lung cancer (SCLC). We and others previously demonstrated that elevated circulating tumour cells (CTC) are associated with worse survival. In the current exploratory study we hypothesized that markers of EMT and CSC in tumour biopsies obtained at diagnosis were associated with overall survival in patients with SCLC.
Methods: Biopsies selected from small cell lung cancer pts study published previously by our group [ Ann Oncol 2012; 23:2937-42] . Epithelial markers [Cytokeratin 8,18,19 (CK; ab41825, Abcam) , EPCAM (VU1D9, cellsignaling), E-cadherin (24E10, cellsignaling)] and mesenchymal markers [Vimentin (V9, Santa Cruz) and c-MET (EP1454Y, Abcam)] were used as biomarkers for EMT. SOX2 (L1D6A2, cellsignaling) and CD44 (IM7, Biolegend) were used as CSC markers. Scoring by two independent observers having no information about clinical outcome. Immuno-Reactive Score (IRS) was made by multiplying percentage (0-6) and intensity (0-3). IRS score>=5 was high, <5 low. Intensity was high >=2 low <2. Data expressed as median with range. 
